الفهرس 
Direct microscope
History of tuberculosis (TB)Only 14 pages are availabe for public view
 |  | from | 191 |  |  |
| | | from | 191 | | |
Abstract
P
ulmonary tuberculosis is a major cause of morbidity and mortality world wide, resulting in the greatest number of deaths due to any one single infectious agent.
Drug resistance threatens global tuberculosis control efforts.
The study included 116 patients admitted to Abassia chest Hospital. The patients were resistant to at least rifampicin and INH. It was done in the period between July 2006 to June 2008. Their files were analysied and the following data were discussed from the files:
1. Full medical history.
• Source of infection
• Whether primary or secondary resistance.
• where did the patients receive anti T.B treatment?
In hospital or at home.
• Whether patients smear positive or negative.
• Pulmonary or extrapulmonary T.B.
• Names and duration of anti-T.B drugs.
• Patients compliance.
• Follow up of anti T.B treatment.
2. Type of the patients:
New, relapse, defaulter and treatment failure.
3. Clinical examination.
4. Radiological examination: chest X-ray.
5. Laboratory investigations:
- CBC - ESR - Creatinine
- SGPT - FBS - 2 HPP
- Direct Zeihl Neelsen smear of sputum.
- Culture and sensitivity on Lowenstein- Jensen media of sputum.
6. Drug sensitivity test to Anti T.B drugs.
7. Regimens of resistance used.
8. Complications of drugs
In this study there were 84 males and 29 females. The mean age was 36.7 year.
According to the occupation of the studied group, employed patients were 76.1% while unemployed were 23.9%.
Special habits detected in the studied group were tobacco smoking, drug addiction and alcohol intake.
According to type of patients, new cases were 4.4% and retreatment patients were 95.6%.
According to type of resistance, acquired resistance was 76.1% primary resistance was 20.4%, uncertain cases were 3.5%.
The most common co-morbidities associated with MDR-TB in the studied group were diabetes, it was 15% and chest diseases as chronic obstructive lung disease was 6.2%.
In the studied group pulmonary TB cases were 96.5% and extrapulmonary were 3.5%.
In the studied group resistance to isoniazid and rifampicin were 100%, resistance to streptomycin was 91.1%, resistance to ethambutol was 79.6%.
In the studied group complications of drug were 84% gastrointestinal manifestations, 58.4% peripheral polyneuritis, 57.5% hypothyroidism, 26.5% depression, 17.7% electrolytes disturbance and 29.2% others as hepatitis, skin manifestions and arthralgia.
In the studied group fate of treatment were 63.8% cured, 15.9% under treatment, 8.8% treatment failure. 7.1% died and 4.4% defaulter.
The most predictors of patients outcome were sputum conversion, number of previous TB treatment, and associated co-morbidities.